---
title: "IN8bio says JCO publication shows INB-200 trial doubles progression-free survival in repeat-dose glioblastoma patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292195555.md"
description: "IN8bio announced that peer-reviewed Phase 1 data published in the Journal of Clinical Oncology shows INB-200 doubled progression-free survival in repeat-dose glioblastoma patients. The median progression-free survival was 16.1 months compared to a ~6.9-month standard-of-care benchmark, with no dose-limiting toxicities or cytokine release syndrome reported."
datetime: "2026-07-09T12:03:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292195555.md)
  - [en](https://longbridge.com/en/news/292195555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292195555.md)
---

# IN8bio says JCO publication shows INB-200 trial doubles progression-free survival in repeat-dose glioblastoma patients

-   IN8bio disclosed peer-reviewed Phase 1 data for INB-200 in newly diagnosed glioblastoma, published in the Journal of Clinical Oncology. \* Repeat-dose patients posted median progression-free survival of 16.1 months, versus a ~6.9-month standard-of-care benchmark; no dose-limiting toxicities reported. \* Across 13 treated patients, median progression-free survival was 9.9 months; median overall survival in repeat-dose patients was 19.5 months versus ~14.6 months historically. \* Safety readout showed no cytokine release syndrome or ICANS in the study. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090800PRIMZONEFULLFEED9759336) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INAB.US](https://longbridge.com/en/quote/INAB.US.md)

## Related News & Research

- [Mizuho Securities Reaffirms Their Buy Rating on IN8bio (INAB)](https://longbridge.com/en/news/295601292.md)
- [IN8bio grants new hire stock option for 4,000 shares under inducement plan](https://longbridge.com/en/news/295443210.md)
- [FDA Issues Warning About Certain Products Containing Toxic Yellow Oleander](https://longbridge.com/en/news/295690341.md)
- [11:02 ETGlobee® Awards Launch THE GLOBEE Achievement Publication, a New Editorial Initiative Highlighting Winner Achievements](https://longbridge.com/en/news/295682544.md)
- [IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation](https://longbridge.com/en/news/295804964.md)